Loading…
Corbus Pharmaceuticals Holdings, Inc. is projected to rise to $12.09 by 2027, a +35% move from its current price of $8.97. CRBP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $8.74 | $8.98 | $9.22 | +0.10% |
| Aug 5 | $8.66 | $8.99 | $9.33 | +0.19% |
| Aug 6 | $8.59 | $9.00 | $9.42 | +0.29% |
| Aug 7 | $8.54 | $9.00 | $9.49 | +0.38% |
| Aug 8 | $8.50 | $9.01 | $9.56 | +0.48% |
| Aug 9 | $8.46 | $9.02 | $9.62 | +0.57% |
| Aug 10 | $8.42 | $9.03 | $9.68 | +0.67% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.42 | $9.03 | $9.68 | +0.67% |
| Week 2 | $8.24 | $9.09 | $10.03 | +1.34% |
| Week 3 | $8.11 | $9.15 | $10.33 | +2.02% |
| Week 4 | $8.01 | $9.21 | $10.59 | +2.70% |
| Week 5 | $7.94 | $9.27 | $10.84 | +3.39% |
| Week 6 | $7.87 | $9.34 | $11.07 | +4.08% |
| Week 7 | $7.82 | $9.40 | $11.30 | +4.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage healthcare company that develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
CRBP trades in the healthcare space with a current price of $8.97. It has a market cap of $166.19M and is ranked 3876 by market capitalization. Near-term technicals show a neutral posture with RSI 50, a SMA50 of $8.69 and a SMA200 of $9.80.
The 30-day range runs from $7.54 to $10.67, and the forecast suggests upside over the longer term, with 2027 avg at $12.09 and 2050 avg at $66.80.
A major floor 17.7% below — a decisive break under it would weaken the trend.
The nearest floor, 8.9% below — buyers have tended to step in here.
The nearest ceiling, 7.9% above — a clean break opens room to run.
A major ceiling 35.5% above — clearing it would confirm fresh momentum.
Key CRBP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRBP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.02 | Sell | $9.02 | Sell |
| MA 10 | $9.03 | Sell | $9.03 | Sell |
| MA 20 | $9.12 | Sell | $9.01 | Sell |
| MA 50 | $8.69 | Buy | $9.02 | Sell |
| MA 100 | $9.34 | Sell | $9.16 | Sell |
| MA 200 | $9.80 | Sell | $9.70 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.57 | Neutral |
| Stoch RSI (14) | 22.24 | Neutral |
| CCI (20) | -50.56 | Neutral |
| Williams %R (14) | -67.31 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -0.44 | Sell |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 32.69 | Neutral |
| TRIX (15) | 0.15 | Buy |
| Awesome (5,34) | 0.15 | Buy |
| Ultimate (7,14,28) | 53.69 | Neutral |
| Momentum (10) | -0.04 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 8.97 | Sell |
| ADX (14) | 7.29 | Neutral |
| ATR (14) | 0.19 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 50. The moving averages paint a similar picture, with SMA50 at $8.69 and SMA200 at $9.80. Support sits at $8.18 and resistance at $9.68, framing a near-term range. The 30-day price range is $7.54 to $10.67, indicating a period of consolidation within that band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.38 | $8.97 | $12.49 | 0% | Neutral | |
| $9.68 | $12.09 | $15.96 | +35% | Bullish | |
| $9.87 | $12.68 | $17.35 | +41% | Bullish | |
| $10.29 | $13.51 | $19.03 | +51% | Bullish | |
| $11.46 | $15.35 | $22.14 | +71% | Bullish | |
| $11.12 | $15.17 | $22.33 | +69% | Bullish | |
| $13.12 | $18.19 | $27.28 | +103% | Bullish | |
| $16.48 | $23.22 | $35.42 | +159% | Bullish | |
| $16.56 | $23.67 | $36.69 | +164% | Bullish | |
| $17.41 | $25.24 | $39.69 | +181% | Bullish | |
| $24.82 | $38.36 | $64.06 | +328% | Bullish | |
| $38.68 | $66.73 | $121.70 | +644% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $7.38 | $8.97 | $10.89 | +0.00% |
| September 2026 | $8.09 | $9.56 | $11.61 | +6.61% |
| October 2026 | $8.23 | $9.78 | $12.00 | +2.31% |
| November 2026 | $8.15 | $9.74 | $12.05 | -0.42% |
| December 2026 | $8.34 | $10.02 | $12.49 | +2.90% |
Click any year to see its month-by-month CRBP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Corbus Pharmaceuticals Holdings, Inc.'s 2026 outlook centres on $8.97, within a $7.38 to $12.49 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CRBP could reach as high as $15.96, with a base case around $12.09 and support toward $9.68 — roughly +35% from $8.97. Buyers look set to stay in control over this stretch.
Expect CRBP to range from $9.87 to $17.35 through 2028. The $12.68 average target implies a +41% move from current prices. That is up +5% on the projected 2027 average. Momentum favours further upside here.
The CRBP price prediction for 2029 points to an average of $13.51 (low $10.29, high $19.03) — a potential gain of +51% on today's $8.97. Buyers look set to stay in control over this stretch.
In 2030, CRBP is projected to trade between $11.46 and $22.14, averaging $15.35 — a potential gain of +71% from today's $8.97. That is up +14% on the projected 2029 average. Momentum favours further upside here.
Corbus Pharmaceuticals Holdings, Inc.'s 2031 outlook centres on $15.17, within a $11.12 to $22.33 range. That is -1% versus the projected 2030 average. That marks a +69% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CRBP could reach as high as $27.28, with a base case around $18.19 and support toward $13.12 — roughly +103% from $8.97. Momentum favours further upside here.
Expect CRBP to range from $16.48 to $35.42 through 2033. The $23.22 average target implies a +159% move from current prices. That is up +28% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The CRBP price prediction for 2034 points to an average of $23.67 (low $16.56, high $36.69) — a potential gain of +164% on today's $8.97. Momentum favours further upside here.
In 2035, CRBP is projected to trade between $17.41 and $39.69, averaging $25.24 — a potential gain of +181% from today's $8.97. That is up +7% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Corbus Pharmaceuticals Holdings, Inc.'s 2040 outlook centres on $38.36, within a $24.82 to $64.06 range. That is up +52% on the projected 2035 average. That marks a +328% change versus current levels. Momentum favours further upside here.
By 2050, CRBP could reach as high as $121.70, with a base case around $66.73 and support toward $38.68 — roughly +644% from $8.97. Buyers look set to stay in control over this stretch.
Investing $1,000 in CRBP today (≈ 111.48272 CRBP) could be worth
$7,439.39
+$6,439.39 (+644%) by 2050 · US Dollar
Based on the average projected CRBP price of $66.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRBPwould be worth at today's price.
$1,000 invested in CRBP on Jul 31, 2025 (≈ 107.87486 CRBP) would be worth
$967.64
-$32.36 (-3.2%) today · 0.97× · US Dollar
Based on a CRBP entry price of $9.27 vs. today's $8.97.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.17 | $978.19 | -2.2% |
| 1 month ago | $9.07 | $988.97 | -1.1% |
| 3 months ago | $10.3 | $870.87 | -12.9% |
| 6 months ago | $8.28 | $1,083.33 | +8.3% |
| 1 year ago | $9.27 | $967.64 | -3.2% |
| All time (5.0y) ago | $39.9 | $224.81 | -77.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRBP forecast.
Our base-case forecast reaches $18.00 around 2032.
Implied market cap at $18.00: $333.5M
The multi-year forecast shows bullish sentiment beginning after 2026. From 2027 onward, the avg price is projected to rise, with 2027 avg $12.09 and ROI 34.7, 2028 avg $12.68 and ROI 41.3, 2029 avg $13.53 and ROI 50.9, and 2030 avg $15.34 and ROI 71.1. Beyond 2030, 2031 avg $15.16 ROI 69, 2032 avg $18.22 ROI 103.1, 2033 avg $23.22 ROI 158.9, 2034 avg $23.66 ROI 163.8, and 2035 avg $25.26 ROI 181.6.
In the longer horizon, 2040 avg $38.35 ROI 327.5 and 2050 avg $66.80 ROI 644.7. These are estimates and not guarantees, reflecting potential upside within the context of substantial uncertainty and volatility.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $15.34, with a min of $11.45 and a max of $22.13, and an ROI of 71.1.
The forecast indicates bullish sentiment from 2027 onward with an avg of $12.09 in 2027 and ROI of 34.7, following a neutral outlook in 2026; these are estimates and not guarantees.
The long-term max forecast is $121.82 in 2050, indicating a potential to exceed $100 in the out years, though these are estimates and not guaranteed.
Current price is $8.97 and market cap is $166.19M.
The 30-day range is $7.54 to $10.67.
Corbus Pharmaceuticals Holdings, Inc. Community Discussion
0Share your Corbus Pharmaceuticals Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.